ClinicalTrials.gg
CompletedNCT02679469Updated Apr 18, 2017Results posted

A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects

A Phase 1 interventional study of nalmefene hydrochloride 10 mg in Alcohol Dependence, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.

Enrollment
11th of 12
7 · median 212
Started
2016
with 1 other
Phase 1
2 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
3 of 12
Otsuka Pharmaceutical Co., Ltd.

Among the 12 studies testing nalmefene in Alcoholism, this one is the 11th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 1, and was the 9th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →

About nalmefene

nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing nalmefene in Alcoholism as a file.
02

Study summary

The safety, tolerability, and pharmacokinetics of nalmefene at a single oral dose of 10 mg in healthy Japanese male subjects will be evaluated.

03

Conditions studied

  • Alcohol Dependence

Browse trials for

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is a Japanese male.
  • The subject is able to read and understand the form (ICF).
  • The subject has a (BMI) ≥ 19 kg/m2 and ≤ 25 kg/m2 at the screening visit.
  • The subject has a resting pulse and heart rate (as read on the ) ≥ 45 bpm and ≤ 100 bpm at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • The subject has taken any prescription drugs, over-the counter medications, vitamin supplements, or supplements containing St. John's Wort (Hypericum perforatum) within 2 weeks prior to Day 1.
  • The subject has a significant history of alcohol abuse, defined as an alcohol intake greater than 21 units per week. (A unit of alcohol is defined as 250 mL of lager/beer, 100 mL of wine, or 25 mL of spirits.)
  • The subject has taken any products within 4 months prior to Day 1.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Nalmefene hydrochloride 10 mg

    nalmefene 10 mg tablet

    Drug: nalmefene hydrochloride 10 mg

06

What researchers measure

Primary outcomes

  1. Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)

    Time frame: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose

  2. Measure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)

    Time frame: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose

  3. Measure the Terminal-phase Elimination Half-life (T1/2)

    Time frame: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose

07

Results

Posted Apr 18, 2017

Participant flow

Participant flow — Overall Study
MilestoneNalmefene Hydrochloride 10 mg
Started7
Completed7
Not completed0

Outcome measures

PrimaryMeasure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)
Time frame:
pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose
Reported as:
Mean · ng/mL
Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)
ng/mLNalmefene Hydrochloride 10 mg
Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)8.88 ± 3.34
PrimaryMeasure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)
Time frame:
pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose
Reported as:
Mean · ng・h/mL
Measure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)
ng・h/mLNalmefene Hydrochloride 10 mg
Measure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)61.8 ± 18.0
PrimaryMeasure the Terminal-phase Elimination Half-life (T1/2)
Time frame:
pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose
Reported as:
Median · hours
Measure the Terminal-phase Elimination Half-life (T1/2)
hoursNalmefene Hydrochloride 10 mg
Measure the Terminal-phase Elimination Half-life (T1/2)12.1 (8.7 to 14.7)

Adverse events

Collected over From consent acquisition until 5 days after administration of Investigational Medicinal Product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nalmefene Hydrochloride 10 mg—0/7 (0%)1/7 (14.3%)
Most frequent other events
Most frequent other events
EventNalmefene Hydrochloride 10 mg
VomitingGastrointestinal disorders1/7
NauseaGastrointestinal disorders1/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nalmefene Hydrochloride 10 mg
<=18 years0
Between 18 and 65 years7
>=65 years0
Age, Continuous
Age, Continuous(years)Nalmefene Hydrochloride 10 mg
Mean21.6 ± 0.8
Sex: Female, Male
Sex: Female, Male(Participants)Nalmefene Hydrochloride 10 mg
Female0
Male7
Region of Enrollment
Region of Enrollment(participants)Nalmefene Hydrochloride 10 mg
Japan7
08

Study locations

1 site
  • Kyusyu
    Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2016
First posted
Feb 10, 2016
Start
Feb 2016
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Apr 18, 2017
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02679469
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Feb 10, 2016
Start date
Feb 2016
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Apr 18, 2017
Last update
Apr 18, 2017

Study contacts

Jun-ichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion